Design (Testphase)
Risk & Weakness
Altman-Z: Distress-Zone
92
Findings
August 3, 2026
last calculated
Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Altmans Insolvenz-Frühwarnung in Reinform: Z″-Score im jüngsten UND in jedem verfügbaren Quartal in der Distress-Zone (< 1,1), dazu schwache Zinsdeckung (< 3). Anders als der strengere Going-Concern-Scanner (der zusätzlich negativen operativen Cashflow verlangt) zeigt dieser Scanner alle Titel, die dauerhaft in der roten Zone notieren. Fundamental gesunde Titel (Piotroski ≥ 5 oder Fundamental-Rating ≥ 55 von 100) sind über die globalen Short-Filter ausgeschlossen. Quelle: Fundamentaldaten.
Global filters: market cap of $50B or less (mega caps are cut from every scanner); 10- and 30-day ADR must be ≥ 1% (too little movement gets cut); fundamentally healthy names (Piotroski ≥ 5 or Fundamental Rating ≥ 55 out of 100) are excluded.
🔔 Watch scanner
Terms in This Scanner Explained
(19)
- ADR (Average Daily Range)
- The average daily swing of a stock in percent - measured over 10 or 30 trading days (columns "ADR 10D/30D"). An ADR of 5% means: on a normal day the gap between the intraday low and high runs about 5%. Traders look for movement - that is why stocks with an ADR under 1% are filtered out globally. Not to be confused with ADR meaning "American Depositary Receipt" (a US certificate for foreign shares) - here ADR always means the daily swing.
- AI Classification
- Our company-by-company assessment of the AI boom based on SEC filings (the last four quarterly 10-Q reports and two annual 10-K reports): "Sells AI" (AI is a revenue source), "Threatened" (AI is a concrete business risk), "Uses AI" (operational use), or "Neutral" (no material AI exposure). Every classification requires at least two direct quote citations - otherwise the column shows "-". Not a quality judgment or a buy recommendation; the full file is on the stock page, methodology at /stocks/ai-rating-methodology.
- Altman Z-Score
- A bankruptcy early-warning system developed by Edward Altman: several balance-sheet ratios are combined into one score. We use the Z″ variant, built from four balance-sheet ratios — it is designed for service companies and non-manufacturers and uses book value instead of market value. Values from 2.6 up are considered a safe zone, values below 1.1 a distress zone with elevated bankruptcy risk; in between lies a grey area. Because the classic Altman Z is calculated differently, the two numbers are not directly comparable. The formula does not fit banks, insurers, or real-estate stocks.
- Analysis (Full Company Analysis)
- If the Analysis column shows "Read," there is an in-depth TickerGuard company analysis for this stock: business model, scanner findings, quarterly results, evidence from SEC filings, plus opportunities and risks. One click opens it directly.
- Avg/Yr 3Y (Average Annual Return)
- The stock's average annual return over the past 3 years. Shows at a glance whether a stock delivers over the long run or just had a short hot streak.
- Earnings Date
- The date of the next quarterly earnings report. Price gaps in either direction are common around this date - that is why we color it red when it is 7 days away or less, and yellow when it is 14 days away or less: elevated risk for fresh positions.
- EPS (Earnings per Share)
- Quarterly earnings divided by the number of shares outstanding. The most important growth metric: if EPS rises strongly over several quarters, the company is earning more money per share.
- Free Cash Flow (FCF)
- Operating cash flow minus capital expenditures - the money left over for everything else (debt paydown, acquisitions, or buybacks). Consistently positive free cash flow is one of the most honest signs of a healthy business model.
- Funda Rating (Fundamental Rating A+ to F)
- Our proprietary fundamental rating from 0 to 100 points with a school-grade rank from A+ to F. 50 points is the average across the universe, 100 the best possible score. Every stock is scored against all others by percentile: growth in earnings and revenue, earnings surprises, analyst estimates, and quality criteria such as margins, cash flow, and balance-sheet strength. Grades: A+ from 95, A from 75, B from 55, C from 45, D from 25, E from 5, F below — A/A+ are the fundamentally strongest stocks in the universe.
- Going Concern
- The assumption in a company's annual report that it can continue operating. If auditors raise "substantial doubt" about this, it is one of the sharpest warnings there is - the company could run out of cash.
- Interest Coverage
- Operating income divided by interest expense: how many times over can the company pay its interest from ongoing operations? Below 1, earnings do not even cover interest - a serious warning sign.
- Long / Short
- Long = betting on rising prices (buying the stock). Short = betting on falling prices (selling borrowed shares to buy them back cheaper later). Our short scanners are warning or watch lists - not buy candidates.
- Market Capitalization (Mkt Cap)
- The market value of the company: share price x total shares outstanding, shown here in billions of dollars. Micro caps (< $0.3B) are small and volatile, mega caps (> $200B) are heavyweights. Our scanner universe is deliberately capped at $50B - we look for stocks with room to run.
- Net Margin
- How much of revenue is left as profit? Net income divided by revenue, in percent. A 20% margin means: out of every dollar of revenue, 20 cents is left as profit. Rising margins are a strong quality signal.
- Operating Cash Flow (OCF)
- The cash that actually flows into the company from day-to-day operations - without accounting effects such as depreciation. A company can report book profits while still burning cash; operating cash flow reveals that.
- Piotroski F-Score
- A balance-sheet health check developed by Joseph Piotroski: 9 yes/no criteria covering earnings, cash flow, leverage, and efficiency produce a score from 0 to 9. Scores of 7 or higher are considered financially very solid, scores under 3 a warning sign.
- Sector & Industry
- Two levels of industry classification: sector is broad (e.g., Technology), industry is narrow (e.g., Semiconductors). Many strategies watch industry strength, because strong stocks are almost always found in strong industries.
- Stage (Weinstein Stages 1-4)
- Stan Weinstein divides every price chart into four stages: Stage 1 = basing (sideways after a downtrend), Stage 2 = uptrend (the only buying stage), Stage 3 = topping, Stage 4 = downtrend (avoid, or short candidate). Measured against the 30-week line (150-day moving average) and its slope.
- Stress RS (Strength on Stress Days)
- A stress day is a day on which both the overall market and the stock's own sector fell at least 0.5%. Stress RS counts on how many of these days the stock still closed green (shown as "g/n" = green days out of n stress days) and turns that into a rating from 1 to 99. High values point to buyers stepping in even on weak days - often a sign of institutional accumulation.
Hit List
Filter ▾
Rating (traffic light)
Stage
Funda Rating
Piotroski
Columns ▾
This scanner's columns
Extra columns
Tip: clicking a column header sorts the table by that column; a second click flips the direction.
| Symbol | Earnings | Avg/Y 3Y | Stress RS | Stage | Funda Rating | Piotroski | MktCap | Industry | AI Rating | Deep Dive | Deep-Dive Report | Sector | Price | YTD | 6 Mo. | 1 Year | Off High | Price Target | RS | EPS Rating | ADR 10D | ADR 30D | Beta | P/E | P/E (f) | P/S | P/B | P/FCF | PEG | EV/EBITDA | EBIT Margin | Gross Margin | Net Margin | ROE | ROA | Debt/Eq | Equity Ratio | Sales +/Y | Growth Score | Div. Yield | Payout Ratio | Altman Z | Inst. % | Short % | Analysts |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| VIAV Viavi Solutions Inc | 08/06 | +127 % | 72 7/25 | Stage 2 | C 48 | 4 of 9 | 9.5 $ | Communication Equipment | Sells AI | — | — | Technology | 37.80 $ | +180.4 % | +159.6 % | +286.8 % | −16.5 % | +74.5 % | 98 | 9 | 8.6 % | 8.4 % | 1.19 | — | 29.6 | 6.9 | 11.0 | 208.4 | 1.34 | 82.0 | 12.2 % | 60.7 % | -4.0 % | -7.0 % | 3.6 % | 7.85 | 33.5 % | +8.4 % | 4 | 0.0 % | 0.0 % | -85.0 | 97.3 % | 6.8 % | 3.8 (9) |
| AIP Arteris Inc | 08/04 | +177 % | 61 6/25 | Stage 2 | C 48 | 3 of 9 | 1.4 $ | Semiconductors | Sells AI | — | — | Technology | 30.10 $ | +165.9 % | +197.1 % | +232.7 % | −3.8 % | +27.8 % | 98 | 42 | 7.1 % | 7.5 % | 1.92 | — | 0.0 | 18.5 | 504.9 | — | — | -7.7 | -38.0 % | 88.8 % | -44.9 % | -1,369.6 % | -17.9 % | 2.11 | 1.8 % | +22.3 % | 6 | 0.0 % | 0.0 % | -3.7 | 61.1 % | 7.3 % | 4.5 (4) |
| OTLK OUTLOOK THERAPEUTICS INC | 08/13 | -32 % | 71 6/22 | Stage 3 | D 29 | 4 of 9 | 0.1 $ | Biotechnology | Uses AI | — | Healthcare | 0.91 $ | +7.6 % | -7.7 % | -52.7 % | −52.5 % | +241.6 % | 97 | 42 | 16.8 % | 20.7 % | 0.78 | — | 2.8 | 450.0 | — | — | — | -4.1 | — | -360.8 % | 0.0 % | -3.7 % | -184.8 % | — | — | +730.9 % | 3 | 0.0 % | 0.0 % | -116.1 | 6.9 % | 10.1 % | — | |
| IBRX Immunitybio Inc | 08/04 | +57 % | 56 5/22 | Stage 2 | C 51 | 3 of 9 | 7.4 $ | Biotechnology | Uses AI | — | Healthcare | 7.20 $ | +269.7 % | +309.8 % | +201.7 % | −37.3 % | +77.1 % | 94 | 42 | 7.8 % | 7.0 % | 0.08 | — | 0.0 | 52.7 | — | — | — | -9.0 | -157.9 % | 99.3 % | 0.0 % | 0.0 % | -34.4 % | — | -134.5 % | +668.3 % | 6 | 0.0 % | 0.0 % | -23.1 | 17.6 % | 34.6 % | 4.6 (5) | |
| PGEN Precigen Inc | 08/11 | +125 % | 39 4/22 | Stage 2 | C 54 | 4 of 9 | 2.4 $ | Biotechnology | Neutral | — | — | Healthcare | 6.60 $ | +28.2 % | +41.3 % | +295.8 % | −2.8 % | +98.4 % | 93 | 42 | 6.5 % | 6.9 % | 1.01 | — | 312.5 | 74.2 | 123.4 | — | — | -3.3 | -25.8 % | -35.4 % | 0.0 % | -1,145.4 % | -42.1 % | 4.86 | 14.6 % | +146.7 % | 2 | 0.0 % | 0.0 % | -57.6 | 71.1 % | 21.2 % | 3.8 (4) |
| ARMP Armata Pharmaceuticals Inc | 08/11 | +51 % | 56 5/22 | Stage 1 | D 29 | 4 of 9 | 0.2 $ | Biotechnology | Neutral | — | — | Healthcare | 5.00 $ | +11.6 % | +0.8 % | +98.8 % | −60.2 % | +169.2 % | 91 | 42 | 11.0 % | 10.5 % | 1.27 | — | 0.0 | 34.7 | — | — | — | -3.5 | — | -215.2 % | 0.0 % | -3,439.4 % | -25.3 % | — | — | -5.2 % | 3 | 0.0 % | 0.0 % | -52.2 | 10.5 % | 1.9 % | — |
| CLPT Clearpoint Neuro Inc | 08/11 | +61 % | 40 4/22 | Stage 3 | D 44 | 4 of 9 | 0.5 $ | Medical Devices | Neutral | — | — | Healthcare | 15.40 $ | +35.5 % | +34.1 % | +53.8 % | −40.3 % | +90.2 % | 90 | 42 | 11.6 % | 9.0 % | 1.24 | — | 12.1 | 11.5 | 24.6 | — | 0.61 | -7.1 | — | 62.3 % | -71.6 % | -149.7 % | -25.0 % | 3.38 | — | +17.8 % | 3 | 0.0 % | 0.0 % | -3.1 | 50.6 % | 12.8 % | 5.0 (2) |
| KPTI Karyopharm Therapeutics Inc | 08/10 | -23 % | 94 9/22 | Stage 2 | D 38 | 4 of 9 | 0.0 $ | Biotechnology | Uses AI | — | — | Healthcare | 2.00 $ | +31.1 % | +35.0 % | -49.9 % | −13.9 % | +42.7 % | 89 | 42 | 7.7 % | 8.7 % | 0.81 | — | 0.0 | 0.3 | 2.5 | — | — | -1.9 | — | 13.5 % | -129.0 % | -891.1 % | -40.6 % | -0.87 | — | +0.6 % | 3 | 0.0 % | 0.0 % | -48.8 | 83.7 % | 24.8 % | — |
| CYTK Cytokinetics Inc | 08/06 | +8 % | 68 6/22 | Stage 2 | D 39 | 3 of 9 | 10.3 $ | Biotechnology | Neutral | — | Healthcare | 76.50 $ | +25.9 % | +36.0 % | +108.4 % | −2.6 % | +39.8 % | 88 | 42 | 4.6 % | 4.1 % | 0.42 | — | 117.6 | 97.1 | 57.1 | — | — | -15.8 | -948.7 % | -290.7 % | 0.0 % | -572.2 % | -31.5 % | -1.56 | -64.9 % | +376.6 % | 3 | 0.0 % | 0.0 % | -7.3 | 118.8 % | 19.4 % | 4.3 (21) | |
| MGTX MeiraGTx Holdings PLC | 08/13 | +23 % | 27 3/22 | Stage 2 | D 33 | 3 of 9 | 1.1 $ | Biotechnology | – | — | — | Healthcare | 11.90 $ | +48.6 % | +51.6 % | +55.3 % | −6.1 % | +148.2 % | 87 | 42 | 6.6 % | 5.8 % | 1.21 | — | 1.6 | 13.8 | 235.6 | — | — | -3.3 | — | 95.4 % | -151.1 % | -368.2 % | -28.1 % | -1.51 | — | +144.6 % | 5 | 0.0 % | 0.0 % | -13.6 | 60.9 % | 6.5 % | 4.6 (5) |
| ECOR Electrocore LLC | 08/05 | +35 % | 70 6/22 | Stage 2 | C 45 | 4 of 9 | 0.1 $ | Medical Devices | – | — | — | Healthcare | 6.10 $ | +86.2 % | +66.4 % | -10.0 % | −31.5 % | +166.6 % | 87 | 42 | 11.0 % | 11.5 % | 0.89 | — | 384.6 | 1.5 | 29.6 | — | — | 0.2 | — | 87.3 % | -44.1 % | -478.7 % | -58.1 % | -1.67 | — | +27.2 % | 6 | 0.0 % | 0.0 % | -44.7 | 9.2 % | 2.6 % | — |
| HURA TuHURA Biosciences Inc | 08/13 | -33 % | 82 7/22 | Stage 3 | E 19 | 3 of 9 | 0.1 $ | Biotechnology | Neutral | — | Healthcare | 2.10 $ | +248.7 % | +177.9 % | -10.8 % | −33.6 % | +210.4 % | 86 | 42 | 10.2 % | 9.0 % | — | — | 0.0 | — | — | — | — | 0.0 | — | — | 0.0 % | -187.2 % | -81.9 % | — | — | — | 2 | 0.0 % | 0.0 % | -16.0 | 15.0 % | 15.8 % | — | |
| BZFD BuzzFeed Inc | 08/06 | -20 % | 75 7/24 | Stage 3 | D 25 | 4 of 9 | 0.1 $ | Internet Content & Information | Threatened | — | — | Communication Services | 1.20 $ | +64.5 % | -12.4 % | -43.5 % | −50.0 % | -25.4 % | 86 | 13 | 10.5 % | 12.3 % | 3.77 | — | 172.4 | 0.5 | — | — | — | -7.7 | — | 40.3 % | -33.3 % | -90.2 % | -5.3 % | — | — | -2.4 % | 2 | 0.0 % | 0.0 % | -12.8 | 10.0 % | 3.2 % | — |
| ATRA Atara Biotherapeutics Inc | 08/10 | -29 % | 81 7/22 | Stage 3 | D 36 | 4 of 9 | 0.1 $ | Biotechnology | – | — | — | Healthcare | 8.60 $ | -38.3 % | -67.1 % | -26.0 % | −46.6 % | +33.7 % | 85 | 42 | 8.3 % | 8.3 % | 0.09 | — | 232.6 | 3.4 | 13.6 | — | — | 2.2 | — | 70.1 % | -40.9 % | -2,014.9 % | -3.8 % | -0.27 | — | -6.3 % | 7 | 0.0 % | 0.0 % | -327.5 | 52.5 % | 7.8 % | — |
| SHIM Shimmick Corporation Common Stock | 08/13 | — | 49 6/29 | Stage 1 | D 41 | 4 of 9 | 0.2 $ | Engineering & Construction | Neutral | — | — | Industrials | 4.10 $ | +25.3 % | +50.2 % | +144.9 % | −39.7 % | +83.8 % | 83 | 42 | 7.6 % | 8.4 % | 0.71 | — | 72.5 | 0.4 | 70.1 | — | — | 1,635.2 | — | 8.7 % | -4.4 % | -696.6 % | -4.3 % | -1.33 | — | +2.6 % | 3 | 0.0 % | 0.0 % | 0.3 | 8.7 % | 0.2 % | — |
| PLUG Plug Power Inc | 08/10 | -24 % | 66 8/29 | Stage 2 | D 43 | 3 of 9 | 2.9 $ | Electrical Equipment & Parts | – | — | — | Industrials | 2.10 $ | +37.6 % | +23.3 % | +48.6 % | −43.9 % | +68.9 % | 82 | 42 | 6.8 % | 8.2 % | 2.17 | — | 13.1 | 4.0 | 3.9 | — | 0.84 | -2.2 | -63.6 % | -31.2 % | -227.1 % | -128.8 % | -13.6 % | 1.35 | 31.7 % | +12.9 % | 2 | 0.0 % | 0.0 % | -10.6 | 68.9 % | 26.7 % | 3.2 (20) |
| IHRT iHeartMedia Inc Class A | 08/10 | +5 % | 50 5/24 | Stage 1 | D 26 | 4 of 9 | 0.6 $ | Broadcasting | – | — | — | Communication Services | 4.00 $ | -6.0 % | -0.4 % | +119.9 % | −37.4 % | +0.7 % | 81 | 89 | 7.6 % | 8.1 % | 2.20 | — | 51.3 | 0.2 | — | — | 5.03 | 19.1 | — | 58.6 % | -7.3 % | -2,444.0 % | 2.7 % | — | — | +0.3 % | 5 | 0.0 % | 0.0 % | 0.7 | 86.6 % | 7.4 % | 2.8 (4) |
| REAL TheRealReal Inc | 08/06 | +260 % | 21 4/31 | Stage 4 | C 54 | 3 of 9 | 1.5 $ | Luxury Goods | Uses AI | — | Consumer Cyclical | 12.50 $ | -22.6 % | -24.8 % | +139.1 % | −28.5 % | +42.6 % | 79 | 42 | 7.3 % | 6.4 % | 2.67 | — | 185.2 | 2.1 | 4.9 | 121.0 | — | 93.7 | -1.2 % | 74.5 % | -9.0 % | -932.7 % | -2.2 % | -1.29 | -93.1 % | +15.4 % | 4 | 0.0 % | 0.0 % | -9.2 | 98.4 % | 17.1 % | 3.6 (7) | |
| ACHV Achieve Life Sciences Inc | 08/06 | -5 % | 56 5/22 | Stage 2 | D 26 | 3 of 9 | 0.6 $ | Biotechnology | – | — | — | Healthcare | 6.30 $ | +0.8 % | +39.7 % | +147.8 % | −7.5 % | +115.6 % | 79 | 42 | 8.7 % | 8.2 % | 2.22 | — | 35.3 | — | — | — | 17.68 | -2.4 | — | — | 0.0 % | -496.2 % | -108.4 % | — | — | -100.0 % | — | 0.0 % | 0.0 % | -29.4 | 61.0 % | 14.4 % | 4.9 (8) |
| RDZN Roadzen Inc. | — | -31 % | 74 7/25 | Stage 1 | C 51 | 4 of 9 | 0.1 $ | Software - Application | Sells AI | — | — | Technology | 1.20 $ | -36.1 % | -24.9 % | +8.9 % | −43.4 % | +244.8 % | 79 | 42 | 9.6 % | 8.4 % | 1.20 | — | 0.0 | 2.0 | — | — | — | -4.4 | — | 61.3 % | -40.9 % | 0.0 % | -20.5 % | — | — | -5.2 % | 5 | 0.0 % | 0.0 % | -20.2 | 3.0 % | 1.2 % | — |
| BKSY Blacksky Technology Inc | 08/06 | +25 % | 99 15/29 | Stage 1 | D 31 | 2 of 9 | 0.9 $ | Specialty Business Services | Sells AI | — | — | Industrials | 23.90 $ | +43.5 % | +33.6 % | +26.7 % | −54.0 % | +75.3 % | 76 | 42 | 9.1 % | 10.7 % | 2.59 | — | 0.0 | 9.3 | — | — | — | 6.6 | — | 69.3 % | -89.1 % | -102.7 % | -10.6 % | — | — | +4.4 % | 5 | 0.0 % | 0.0 % | -2.1 | 68.4 % | 21.7 % | 5.0 (6) |
| ALLO Allogene Therapeutics Inc | 08/12 | -19 % | 16 2/22 | Stage 2 | D 33 | 2 of 9 | 0.6 $ | Biotechnology | – | — | — | Healthcare | 1.80 $ | +51.1 % | +58.6 % | +70.4 % | −53.8 % | +373.7 % | 75 | 42 | 6.7 % | 6.7 % | 0.46 | — | 0.0 | — | — | — | — | -1.0 | — | — | 0.0 % | -52.3 % | -26.0 % | — | — | -100.0 % | 4 | 0.0 % | 0.0 % | -10.0 | 53.3 % | 19.2 % | 4.4 (14) |
| NPCE Neuropace Inc | 08/11 | +85 % | — | Stage 2 | C 49 | 2 of 9 | 0.0 $ | Medical Devices | – | — | — | Healthcare | 13.50 $ | +3.1 % | +2.1 % | +50.2 % | −16.5 % | +22.2 % | 74 | 50 | 4.7 % | 4.7 % | 1.89 | — | 0.0 | — | 33.7 | — | — | -16.9 | — | 78.3 % | -21.7 % | -111.4 % | -10.0 % | 4.88 | — | +25.1 % | 4 | 0.0 % | 0.0 % | -11.4 | 96.3 % | 2.1 % | — |
| IMDX Insight Molecular Diagnostics Inc. | 08/10 | +11 % | 57 5/22 | Stage 4 | D 37 | 2 of 9 | 0.2 $ | Diagnostics & Research | Neutral | — | — | Healthcare | 5.00 $ | -28.4 % | -6.9 % | +96.5 % | −34.3 % | +49.1 % | 74 | 42 | 8.9 % | 10.6 % | 1.77 | — | 0.0 | 83.7 | 77.9 | — | — | -1.3 | — | 51.1 % | 0.0 % | -23,603.1 % | -43.4 % | -0.29 | — | +115.6 % | 5 | 0.0 % | 0.0 % | -34.6 | 61.4 % | 7.2 % | — |
| CDXS Codexis Inc | 08/12 | -5 % | 16 2/22 | Stage 2 | C 49 | 4 of 9 | 0.1 $ | Biotechnology | – | — | — | Healthcare | 1.50 $ | +46.6 % | +38.7 % | -46.1 % | −41.9 % | +192.6 % | 73 | 42 | 6.9 % | 6.5 % | 2.50 | — | 149.3 | 1.8 | — | — | 13.53 | -10.7 | — | 23.8 % | -41.0 % | -68.9 % | -12.5 % | — | — | +18.6 % | 3 | 0.0 % | 0.0 % | -10.0 | 74.4 % | 3.6 % | — |
| EBC Eastern Bankshares Inc | 07/23 | +33 % | 1 0/22 | Stage 2 | C 52 | 4 of 9 | 4.9 $ | Banks - Regional | – | — | — | Financial Services | 23.10 $ | +15.5 % | +19.3 % | +58.1 % | −3.2 % | +9.2 % | 64 | 78 | 2.3 % | 2.3 % | 0.68 | 12.9 | 12.3 | 3.5 | 1.2 | 13.8 | — | 0.0 | 45.9 % | 100.0 % | 34.3 % | 9.4 % | 1.3 % | 0.22 | 14.0 % | -1.2 % | 4 | 2.4 % | 31.8 % | -1.5 | 81.3 % | 8.4 % | 4.0 (4) |
| FMBH First Mid Illinois Bancshares Inc | 07/23 | +34 % | 2 0/22 | Stage 2 | C 53 | 4 of 9 | 1.4 $ | Banks - Regional | – | — | — | Financial Services | 52.50 $ | +21.9 % | +20.7 % | +43.7 % | −3.2 % | +8.4 % | 64 | 61 | 2.8 % | 2.5 % | 0.79 | — | 12.0 | 3.1 | — | 13.8 | 1.27 | 0.0 | 40.5 % | 100.0 % | 26.9 % | 9.9 % | 1.2 % | — | 11.6 % | +4.2 % | 5 | 2.0 % | 23.0 % | -1.4 | 53.6 % | 2.1 % | 3.9 (7) |
| BBIO BridgeBio Pharma Inc | 08/04 | +113 % | 68 6/22 | Stage 1 | C 54 | 3 of 9 | 15.7 $ | Biotechnology | – | — | — | Healthcare | 80.00 $ | -10.3 % | -5.9 % | +68.8 % | −18.0 % | +31.4 % | 59 | 42 | 3.7 % | 4.0 % | 0.95 | — | 0.0 | 27.0 | 142.0 | — | — | -9.4 | -54.5 % | 95.1 % | -124.4 % | -1,789.7 % | -28.0 % | -1.49 | -165.5 % | +126.3 % | 4 | 0.0 % | 0.0 % | -7.9 | 103.2 % | 14.7 % | 4.4 (19) |
| AQST Aquestive Therapeutics Inc | 08/10 | +58 % | 28 3/22 | Stage 3 | C 47 | 3 of 9 | 0.5 $ | Drug Manufacturers - Specialty & Generic | – | — | — | Healthcare | 3.80 $ | -22.1 % | -30.3 % | -0.8 % | −40.9 % | +140.2 % | 59 | 42 | 6.5 % | 5.1 % | 1.45 | — | 0.0 | 9.5 | 12.0 | — | — | -1.8 | — | 63.4 % | -137.1 % | 0.0 % | -28.7 % | -3.92 | — | -22.6 % | 3 | 0.0 % | 0.0 % | -5.4 | 60.6 % | 13.9 % | 4.6 (9) |
| BIRD Allbirds Inc | 08/06 | -32 % | 21 4/31 | Stage 3 | E 17 | 3 of 9 | 0.0 $ | Apparel Retail | – | — | — | Consumer Cyclical | 2.30 $ | +24.9 % | -84.6 % | -76.3 % | −82.4 % | +227.1 % | 57 | 42 | 23.0 % | 13.8 % | 2.56 | — | 0.0 | 0.2 | 1.4 | — | — | -0.6 | — | 38.1 % | -53.4 % | -153.7 % | -38.8 % | 2.04 | — | -19.7 % | 1 | 0.0 % | 0.0 % | -23.1 | 35.4 % | 16.9 % | — |
| W Wayfair Inc | 08/03 | +16 % | 8 2/31 | Stage 4 | D 42 | 3 of 9 | 11.8 $ | Internet Retail | – | — | — | Consumer Cyclical | 89.30 $ | -15.5 % | -5.0 % | +36.9 % | −22.1 % | +12.7 % | 56 | 13 | 6.5 % | 6.8 % | 2.96 | — | 30.7 | 0.9 | 2,558.6 | 25.9 | 23.50 | 107.7 | 0.4 % | 30.4 % | -2.4 % | 0.0 % | 3.7 % | -1.28 | -99.0 % | +5.1 % | 3 | 0.0 % | 0.0 % | -4.4 | 113.3 % | 18.1 % | 3.8 (35) |
| EDIT Editas Medicine Inc | 08/11 | -27 % | 29 3/22 | Stage 3 | D 42 | 2 of 9 | 0.4 $ | Biotechnology | Neutral | — | Healthcare | 2.70 $ | +27.8 % | +27.2 % | +8.6 % | −36.9 % | +130.8 % | 54 | 42 | 8.7 % | 10.1 % | 2.10 | — | 0.0 | 10.7 | 96.2 | — | — | -1.4 | -883.2 % | -109.2 % | -281.6 % | -326.1 % | -27.0 % | 0.40 | 14.6 % | +25.4 % | 4 | 0.0 % | 0.0 % | -11.5 | 49.4 % | 14.5 % | 3.5 (15) | |
| MNKD MannKind Corp | 08/05 | +0 % | 69 6/22 | Stage 4 | D 38 | 2 of 9 | 1.2 $ | Biotechnology | Uses AI | — | Healthcare | 3.80 $ | -30.7 % | -28.5 % | +1.3 % | −39.6 % | +97.9 % | 53 | 19 | 5.3 % | 5.9 % | 1.09 | — | 41.3 | 3.2 | 181.6 | 91.4 | 4.39 | 51.0 | -3.3 % | 75.6 % | -6.6 % | 0.0 % | 2.0 % | -7.38 | -8.0 % | +22.2 % | 5 | 0.0 % | 0.0 % | -9.8 | 59.3 % | 9.3 % | 4.9 (7) | |
| EOLS Evolus Inc | 08/04 | -5 % | 40 4/22 | Stage 3 | C 46 | 4 of 9 | 0.4 $ | Drug Manufacturers - Specialty & Generic | – | — | — | Healthcare | 6.10 $ | +1.4 % | +4.1 % | -33.9 % | −29.9 % | +152.9 % | 52 | 42 | 4.7 % | 4.9 % | 1.32 | — | 53.2 | 1.3 | — | — | — | -21.5 | — | 66.1 % | -14.4 % | -18,729.6 % | -9.1 % | — | — | +11.6 % | 4 | 0.0 % | 0.0 % | -5.4 | 70.1 % | 9.1 % | 4.6 (7) |
| OBIO Orchestra BioMed Holdings Inc. | 08/11 | -17 % | 7 1/22 | Stage 1 | D 39 | 3 of 9 | 0.2 $ | Biotechnology | – | — | — | Healthcare | 4.10 $ | -2.7 % | +9.7 % | +68.9 % | −28.1 % | +212.0 % | 52 | 42 | 6.7 % | 5.4 % | 0.48 | — | 0.0 | 7.5 | 6.5 | — | — | -1.8 | — | 99.5 % | -167.0 % | -161.1 % | -43.0 % | 0.66 | — | +1,169.2 % | 7 | 0.0 % | 0.0 % | -6.3 | 41.7 % | 3.4 % | — |
| GEG Great Elm Group Inc | 09/01 | +6 % | 70 6/22 | Stage 3 | E 24 | 4 of 9 | 0.1 $ | Asset Management | – | — | — | Financial Services | 2.40 $ | -4.3 % | -7.8 % | +11.3 % | −35.9 % | +722.2 % | 50 | 53 | 11.0 % | 6.2 % | 0.57 | — | 42.7 | 3.1 | 1.9 | 6.1 | 0.77 | 0.4 | — | -16.5 % | -100.5 % | -42.3 % | -6.7 % | 1.59 | — | -8.5 % | 4 | 48.8 % | 0.0 % | -87.5 | 40.1 % | 3.8 % | — |
| UBCP United Bancorp Inc | 07/30 | +21 % | 97 10/22 | Stage 2 | C 53 | 4 of 9 | 0.1 $ | Banks - Regional | – | — | — | Financial Services | 15.70 $ | +13.4 % | +13.9 % | +18.8 % | −9.1 % | +26.8 % | 49 | 53 | 3.3 % | 3.1 % | 0.36 | 12.1 | 10.3 | 1.9 | 1.4 | 18.4 | — | 0.0 | — | 100.0 % | 24.1 % | 12.2 % | 0.9 % | 1.74 | — | +8.0 % | 5 | 4.7 % | 68.8 % | -0.7 | 13.5 % | 0.2 % | — |
| RARE Ultragenyx | 08/04 | -14 % | 69 6/22 | Stage 3 | D 37 | 0 of 9 | 2.5 $ | Biotechnology | – | — | — | Healthcare | 25.00 $ | +25.0 % | -11.3 % | -12.0 % | −31.0 % | +114.3 % | 48 | 42 | 5.5 % | 5.2 % | 0.31 | — | 0.0 | 3.7 | — | — | — | -6.5 | -102.2 % | -28.1 % | -90.9 % | -608.5 % | -25.5 % | — | -18.2 % | +20.1 % | 3 | 0.0 % | 0.0 % | -9.9 | 104.2 % | 14.1 % | 4.6 (20) |
| OSTX OS Therapies Incorporated | 08/17 | — | 82 7/22 | Stage 3 | D 27 | 2 of 9 | 0.1 $ | Biotechnology | – | — | — | Healthcare | 1.60 $ | +30.0 % | +47.4 % | -11.4 % | −30.0 % | +422.1 % | 45 | 42 | 8.5 % | 8.3 % | — | — | 1.7 | — | 12.1 | — | — | 0.0 | — | — | 0.0 % | -914.0 % | -366.6 % | -0.12 | — | — | — | 0.0 % | 0.0 % | -78.9 | 6.5 % | 4.9 % | — |
| TCBX Third Coast Bancshares, Inc. | 07/22 | +45 % | — | Stage 3 | C 50 | 4 of 9 | 0.0 $ | Banks - Regional | – | — | — | Financial Services | 44.00 $ | +4.9 % | +1.1 % | +21.0 % | −8.0 % | +5.9 % | 44 | 50 | 2.5 % | 2.4 % | 0.65 | 10.9 | 10.4 | — | 1.1 | — | — | 0.0 | — | 100.0 % | 32.4 % | 12.2 % | 1.2 % | 0.24 | — | +8.5 % | 4 | 0.0 % | 0.0 % | -1.5 | 57.0 % | 3.0 % | — |
| SPCE Virgin Galactic Holdings Inc | 08/05 | -32 % | 18 3/29 | Stage 1 | D 40 | 3 of 9 | 0.3 $ | Aerospace & Defense | Neutral | — | Industrials | 2.80 $ | -6.5 % | -12.0 % | -23.4 % | −71.9 % | +42.0 % | 43 | 42 | 11.4 % | 18.9 % | 2.74 | — | 0.0 | 236.9 | — | — | — | -0.1 | — | -6,127.7 % | 0.0 % | -104.5 % | -19.8 % | — | — | -78.1 % | 2 | 0.0 % | 0.0 % | -10.8 | 15.8 % | 32.4 % | — | |
| CNVS Cineverse Corp. | 08/13 | +12 % | 84 8/24 | Stage 3 | D 34 | 1 of 9 | 0.1 $ | Entertainment | – | — | — | Communication Services | 2.50 $ | +35.1 % | +34.0 % | -51.6 % | −63.7 % | +291.8 % | 43 | 42 | 10.7 % | 7.1 % | 1.52 | — | 38.8 | 0.9 | — | — | 0.46 | 10.1 | — | 53.4 % | -13.4 % | -24.5 % | -9.3 % | — | — | +59.1 % | 2 | 0.0 % | 0.0 % | -20.6 | 16.5 % | 2.7 % | — |
| BCRX BioCryst Pharmaceuticals Inc | 08/03 | +11 % | 80 7/22 | Stage 2 | D 42 | 2 of 9 | 2.2 $ | Drug Manufacturers - Specialty & Generic | – | — | — | Healthcare | 8.80 $ | +19.4 % | +24.0 % | +10.8 % | −9.5 % | +133.3 % | 42 | 42 | 5.9 % | 4.7 % | 0.54 | — | 87.0 | 2.5 | 50.3 | 7.5 | 9.39 | 7.2 | -2.5 % | 76.6 % | -51.7 % | -1,925.4 % | 42.6 % | -1.55 | -119.1 % | +94.1 % | 7 | 0.0 % | 0.0 % | -15.9 | 101.1 % | 12.4 % | 4.4 (12) |
| ELUT Elutia Inc. | 08/13 | -20 % | 93 9/22 | Stage 2 | D 32 | 3 of 9 | 0.0 $ | Medical Devices | – | — | — | Healthcare | 0.87 $ | +48.7 % | +71.0 % | -57.5 % | −64.1 % | +426.3 % | 41 | 42 | 7.1 % | 8.1 % | 0.85 | — | 0.0 | 2.8 | 1.8 | — | — | -3.3 | — | 56.3 % | 400.2 % | 0.0 % | -26.4 % | 0.52 | — | -49.6 % | — | 0.0 % | 0.0 % | -7.2 | 45.7 % | 0.1 % | — |
| NG NovaGold Resources Inc | — | +19 % | 11 2/23 | Stage 4 | D 29 | 4 of 9 | 2.6 $ | Gold | – | — | — | Basic Materials | 5.90 $ | -22.5 % | -39.5 % | +12.7 % | −57.3 % | +139.8 % | 40 | 42 | 8.2 % | 6.7 % | 2.15 | — | 4.9 | — | — | — | 1.34 | -40.4 | 0.0 % | — | 0.0 % | -52.0 % | -4.4 % | — | 70.3 % | -100.0 % | 1 | 0.0 % | 0.0 % | -2.2 | 79.3 % | 8.3 % | 4.4 (8) |
| BETR Better Home & Finance Holding Company | 08/12 | -33 % | — | Stage 4 | D 42 | 3 of 9 | 0.0 $ | Mortgage Finance | – | — | — | Financial Services | 27.30 $ | -21.1 % | -28.2 % | +104.5 % | −72.8 % | +61.1 % | 40 | 50 | 9.0 % | 8.7 % | 1.73 | — | 0.0 | — | — | — | — | -0.9 | — | 100.0 % | -102.5 % | -875.5 % | -13.2 % | — | — | +59.4 % | 4 | 0.0 % | 0.0 % | -1.0 | 46.6 % | 23.1 % | — |
| GRPN Groupon Inc | 08/05 | +68 % | 84 8/24 | Stage 3 | D 36 | 3 of 9 | 1.1 $ | Internet Content & Information | Uses AI | — | Communication Services | 27.70 $ | -4.8 % | +29.9 % | -4.9 % | −46.9 % | -4.6 % | 38 | 86 | 9.3 % | 8.9 % | 0.22 | — | 153.8 | 2.1 | 21.5 | 26.4 | 14.66 | 17.4 | — | 90.7 % | -20.8 % | -15.2 % | 0.8 % | -5.02 | — | +1.2 % | 4 | 0.0 % | 0.0 % | -7.0 | 148.1 % | 59.9 % | 4.0 (4) | |
| SABR Sabre Corporation | 08/06 | -15 % | 73 7/25 | Stage 3 | C 46 | 4 of 9 | 0.8 $ | Software - Infrastructure | Sells AI | — | Technology | 2.00 $ | +28.7 % | +47.2 % | -32.8 % | −46.9 % | +4.7 % | 36 | 6 | 9.0 % | 7.4 % | 0.96 | — | 37.7 | 0.3 | 155.2 | — | 1.68 | 12.7 | — | 56.5 % | 17.6 % | -737.4 % | 5.1 % | -4.10 | — | -8.5 % | 4 | 0.0 % | 0.0 % | 0.0 | 90.2 % | 11.0 % | 3.7 (7) | |
| NN Nextnav Acquisition Corp | 08/05 | +156 % | 95 11/25 | Stage 1 | E 21 | 3 of 9 | 1.8 $ | Software - Infrastructure | Neutral | — | — | Technology | 13.20 $ | +2.9 % | +4.6 % | -10.6 % | −31.7 % | +157.0 % | 35 | 42 | 7.7 % | 8.5 % | 1.07 | — | 0.0 | 449.0 | 189.2 | — | — | -1.6 | -1,913.9 % | -101.8 % | 0.0 % | -706.8 % | -17.3 % | -3.13 | -38.2 % | -19.3 % | 2 | 0.0 % | 0.0 % | -11.9 | 71.0 % | 15.9 % | 4.0 (2) |
| ELWT Elauwit Connection, Inc. Common Stock | 08/13 | — | 94 10/24 | Stage 1 | D 36 | 3 of 9 | 0.1 $ | Telecom Services | – | — | — | Communication Services | 8.70 $ | +18.9 % | +30.7 % | — | −36.8 % | +95.4 % | 31 | 42 | 10.5 % | 10.2 % | — | — | 0.0 | 2.8 | 25.3 | — | — | 0.0 | — | 17.3 % | -28.9 % | 0.0 % | -35.6 % | 0.82 | — | +154.5 % | 5 | 0.0 % | 0.0 % | -4.6 | 8.6 % | 1.1 % | — |
| CDZI Cadiz Inc | 08/12 | +1 % | 50 3/15 | Stage 4 | D 39 | 3 of 9 | 0.3 $ | Utilities - Regulated Water | – | — | — | Utilities | 3.10 $ | -27.5 % | -32.0 % | +2.7 % | −47.6 % | +219.6 % | 29 | 42 | 6.6 % | 6.7 % | 1.83 | — | 14.9 | 17.4 | — | — | 1.51 | -25.1 | — | 31.4 % | -221.4 % | -111.3 % | -10.7 % | — | — | +69.8 % | 4 | 0.0 % | 0.0 % | -12.9 | 48.8 % | 12.5 % | — |
| GROV Grove Collaborative Holdings, Inc. | 08/06 | -9 % | 65 4/16 | Stage 4 | C 45 | 4 of 9 | 0.0 $ | Household & Personal Products | – | — | — | Consumer Defensive | 1.10 $ | +10.9 % | +9.4 % | -21.0 % | −32.1 % | +60.0 % | 28 | 42 | 5.6 % | 6.3 % | 1.04 | — | 0.1 | 0.3 | — | — | — | -3.4 | — | 54.1 % | -5.5 % | -89.6 % | -9.8 % | — | — | -14.6 % | 3 | 0.0 % | 0.0 % | -38.9 | 30.4 % | 9.3 % | — |
| PACB Pacific Biosciences of California | 08/06 | -30 % | 15 2/22 | Stage 4 | D 32 | 3 of 9 | 0.4 $ | Medical Devices | – | — | — | Healthcare | 1.40 $ | -29.9 % | -8.0 % | +6.8 % | −41.4 % | +75.6 % | 26 | 42 | 8.6 % | 8.4 % | 2.29 | — | 0.0 | 2.7 | 189.5 | — | — | 140.8 | — | 38.3 % | -80.4 % | -273.6 % | -12.0 % | 297.29 | — | +3.9 % | 2 | 0.0 % | 0.0 % | -6.5 | 54.0 % | 17.1 % | 3.8 (14) |
| MDAI Spectral AI Inc. | 08/11 | -28 % | 70 6/22 | Stage 3 | D 27 | 1 of 9 | 0.0 $ | Medical Devices | – | — | — | Healthcare | 1.60 $ | +20.4 % | +17.4 % | -31.8 % | −48.0 % | +224.4 % | 26 | 42 | 4.9 % | 7.9 % | 1.17 | — | 52.4 | 2.8 | — | — | — | -3.4 | — | 46.0 % | -82.0 % | -2,308.3 % | -31.5 % | — | — | -33.6 % | 5 | 0.0 % | 0.0 % | -14.9 | 15.2 % | 10.5 % | — |
| OM Outset Medical Inc | 08/05 | -33 % | 7 1/22 | Stage 3 | D 37 | 4 of 9 | 0.1 $ | Medical Devices | – | — | — | Healthcare | 5.00 $ | +28.3 % | +31.6 % | -66.8 % | −78.5 % | +67.0 % | 24 | 42 | 11.0 % | 9.7 % | 1.94 | — | 0.0 | 0.8 | — | — | — | -0.2 | — | 40.6 % | -63.7 % | -53.2 % | -15.3 % | — | — | +5.1 % | 3 | 0.0 % | 0.0 % | -7.8 | 84.2 % | 14.5 % | — |
| FTCI FTC Solar Inc | 08/04 | -30 % | 62 6/25 | Stage 4 | C 53 | 4 of 9 | 0.0 $ | Solar | – | — | — | Technology | 2.90 $ | -52.2 % | -58.7 % | -52.3 % | −64.2 % | +124.8 % | 22 | 42 | 9.6 % | 9.9 % | 1.81 | — | 18.8 | 0.5 | 7.8 | — | — | -0.7 | — | 1.4 % | -44.9 % | -955.8 % | -25.3 % | -3.81 | — | +110.5 % | 3 | 0.0 % | 0.0 % | -10.6 | 10.1 % | 9.0 % | — |
| BKKT Bakkt Holdings Inc | 08/10 | -30 % | 20 3/25 | Stage 4 | E 19 | 3 of 9 | 0.3 $ | Software - Infrastructure | – | — | — | Technology | 7.40 $ | -11.7 % | -23.3 % | -21.2 % | −84.3 % | +142.7 % | 20 | 42 | 9.7 % | 10.7 % | 5.90 | — | 0.0 | 0.2 | 2.1 | — | — | 0.8 | — | -6.9 % | -8.4 % | -102.0 % | -37.4 % | 0.00 | — | -33.1 % | 4 | 0.0 % | 0.0 % | -7.7 | 21.4 % | 25.0 % | — |
| TVGN Tevogen Bio Holdings Inc. | 08/18 | -33 % | 58 5/22 | Stage 4 | E 19 | 4 of 9 | 0.0 $ | Biotechnology | – | — | — | Healthcare | 7.00 $ | -42.5 % | -68.2 % | -86.0 % | −20.7 % | -79.0 % | 20 | 42 | 12.9 % | 16.1 % | 0.22 | — | 0.0 | — | 0.0 | — | — | 18.3 | — | — | 0.0 % | 0.0 % | -294.4 % | -0.31 | — | — | — | 0.0 % | 0.0 % | -129.5 | 3.6 % | 5.3 % | — |
| EVLV Evolv Technologies Holdings Inc | 08/13 | -2 % | 85 10/29 | Stage 4 | C 47 | 3 of 9 | 1.0 $ | Security & Protection Services | – | — | — | Industrials | 5.70 $ | -22.6 % | -15.8 % | -15.9 % | −41.3 % | +84.1 % | 19 | 42 | 4.8 % | 4.8 % | 1.77 | — | 43.3 | 6.4 | 8.9 | — | — | -5.1 | — | 49.8 % | -22.8 % | -30.2 % | -5.8 % | 0.35 | — | +40.5 % | 6 | 0.0 % | 0.0 % | -0.5 | 72.9 % | 5.2 % | 4.5 (4) |
| SERA Sera Prognostics Inc | 08/05 | -31 % | 58 5/22 | Stage 4 | D 32 | 2 of 9 | 0.1 $ | Medical Devices | – | — | — | Healthcare | 2.10 $ | -37.6 % | -49.7 % | -22.2 % | −56.0 % | +205.6 % | 15 | 42 | 6.5 % | 9.2 % | 0.97 | — | 0.0 | — | 1.2 | — | — | -0.6 | — | -191.2 % | 0.0 % | -39.6 % | -21.6 % | 0.04 | — | +5.2 % | 4 | 0.0 % | 0.0 % | -5.6 | 63.1 % | 0.9 % | — |
| OWLT Owlet Inc | 08/06 | +3 % | 16 2/22 | Stage 4 | D 40 | 3 of 9 | 0.2 $ | Medical Devices | – | — | — | Healthcare | 5.40 $ | -67.4 % | -62.5 % | -26.5 % | −68.5 % | +143.4 % | 12 | 42 | 9.0 % | 7.4 % | 1.84 | — | 0.0 | 1.4 | — | — | — | -0.6 | — | 50.9 % | -43.0 % | -526.2 % | -10.0 % | — | — | +35.4 % | 6 | 0.0 % | 0.0 % | -8.5 | 74.4 % | 2.4 % | — |
| COCH Envoy Medical Inc. | 07/30 | -33 % | 93 9/22 | Stage 4 | D 27 | 4 of 9 | 0.1 $ | Medical Devices | – | — | — | Healthcare | 0.69 $ | -1.7 % | -8.8 % | -52.2 % | −64.4 % | +273.1 % | 11 | 42 | 10.6 % | 7.5 % | 1.86 | — | 0.0 | 270.0 | — | — | — | -1.4 | — | -229.5 % | 0.0 % | 0.0 % | -71.3 % | — | — | +7.1 % | 3 | 0.0 % | 0.0 % | -32.6 | 22.9 % | 2.5 % | — |
| LUNG Pulmonx Corp | 07/29 | -30 % | — | Stage 4 | D 34 | 3 of 9 | 0.0 $ | Medical Devices | – | — | — | Healthcare | 2.10 $ | -42.1 % | -41.7 % | +31.7 % | −67.8 % | +172.0 % | 10 | 50 | 8.4 % | 7.8 % | 0.31 | — | 28.3 | — | — | — | — | -5.6 | — | 75.5 % | -60.1 % | -86.2 % | -24.0 % | — | — | +8.0 % | 4 | 0.0 % | 0.0 % | -9.4 | 79.1 % | 6.4 % | — |
| AEYE AudioEye Inc | 08/06 | +3 % | 20 3/25 | Stage 4 | D 41 | 4 of 9 | 0.1 $ | Software - Application | – | — | — | Technology | 5.90 $ | -40.1 % | -47.6 % | -50.3 % | −63.5 % | +163.4 % | 10 | 42 | 7.2 % | 6.7 % | 0.82 | — | 7.0 | 1.7 | 23.8 | 11.5 | 2.16 | 567.8 | — | 78.0 % | -9.0 % | -66.9 % | -7.6 % | 5.33 | — | +14.5 % | 5 | 0.0 % | 0.0 % | -7.1 | 36.5 % | 5.7 % | — |
| TELA Tela Bio Inc | 08/10 | -31 % | 94 9/22 | Stage 4 | D 35 | 4 of 9 | 0.0 $ | Medical Devices | – | — | — | Healthcare | 0.74 $ | -33.4 % | -35.9 % | -60.2 % | −66.4 % | +204.1 % | 10 | 42 | 12.2 % | 11.7 % | 1.34 | — | 0.0 | 0.5 | 7.3 | — | — | -5.0 | — | 67.7 % | -49.3 % | -616.6 % | -28.7 % | -10.84 | — | +15.8 % | 4 | 0.0 % | 0.0 % | -14.8 | 69.0 % | 1.0 % | — |
| VSTM Verastem Inc | 08/06 | -17 % | 40 4/22 | Stage 4 | D 35 | 3 of 9 | 0.5 $ | Biotechnology | – | — | — | Healthcare | 5.70 $ | -45.5 % | -51.5 % | -6.4 % | −69.3 % | +158.6 % | 9 | 42 | 8.6 % | 7.4 % | 0.29 | — | 0.0 | 10.1 | 6.7 | — | — | -0.2 | — | 85.1 % | 0.0 % | -786.2 % | -59.4 % | 1.05 | — | +209.1 % | 4 | 0.0 % | 0.0 % | -15.1 | 93.6 % | 23.0 % | 4.8 (9) |
| CVRX CVRx Inc | 08/03 | -21 % | 89 8/22 | Stage 4 | D 37 | 3 of 9 | 0.2 $ | Medical Devices | – | — | — | Healthcare | 5.50 $ | -27.5 % | -22.7 % | -27.3 % | −53.5 % | +112.7 % | 9 | 42 | 6.8 % | 7.0 % | 0.78 | — | 0.0 | 2.6 | — | — | — | -1.3 | — | 86.2 % | -89.1 % | -107.0 % | -27.3 % | — | — | +10.5 % | 5 | 0.0 % | 0.0 % | -13.5 | 63.6 % | 9.3 % | — |
| CRGO Freightos Limited Ordinary shares | 08/17 | -20 % | 60 7/29 | Stage 4 | C 53 | 3 of 9 | 0.1 $ | Integrated Freight & Logistics | – | — | — | Industrials | 1.20 $ | -36.8 % | -40.7 % | -57.8 % | −67.9 % | +105.9 % | 9 | 42 | 6.7 % | 7.6 % | 1.16 | — | 0.0 | 2.0 | 1.7 | — | — | -1.1 | — | 66.8 % | -65.6 % | -43.8 % | -18.4 % | 0.06 | — | +23.9 % | 6 | 0.0 % | 0.0 % | -8.5 | 26.0 % | 0.6 % | — |
| WGS GeneDx Holdings Corp. | 08/04 | +283 % | 39 4/22 | Stage 4 | D 40 | 2 of 9 | 1.9 $ | Diagnostics & Research | – | — | — | Healthcare | 67.90 $ | -55.3 % | -49.2 % | -33.2 % | −59.8 % | +25.6 % | 8 | 42 | 7.9 % | 8.0 % | 1.91 | — | 204.1 | 4.4 | 8.1 | — | — | 161.2 | — | 69.6 % | -17.6 % | -30.4 % | -4.4 % | 0.66 | — | +40.0 % | 8 | 0.0 % | 0.0 % | -3.6 | 114.7 % | 37.8 % | 4.7 (6) |
| ALDX Aldeyra Therapeutics, Inc. | 08/06 | -24 % | 70 6/22 | Stage 4 | C 47 | 1 of 9 | 0.1 $ | Biotechnology | – | — | — | Healthcare | 1.50 $ | -61.0 % | -61.2 % | -68.2 % | −70.9 % | +322.2 % | 8 | 42 | 9.5 % | 8.5 % | 1.15 | — | 0.0 | — | 2.1 | — | — | 7.0 | — | — | 0.0 % | -51.8 % | -22.2 % | 0.37 | — | — | 4 | 0.0 % | 0.0 % | -17.3 | 62.8 % | 11.8 % | — |
| RMTI Rockwell Medical Inc | 08/13 | -28 % | 58 5/22 | Stage 4 | D 26 | 4 of 9 | 0.0 $ | Drug Manufacturers - Specialty & Generic | – | — | — | Healthcare | 7.20 $ | -19.9 % | -27.4 % | -24.4 % | −69.0 % | +4,515.4 % | 8 | 42 | 6.4 % | 5.9 % | 1.62 | — | 33.0 | 0.5 | 0.8 | 18.3 | 4.43 | 22.1 | — | 17.1 % | -8.0 % | -16.0 % | -5.4 % | 0.40 | — | -31.8 % | 2 | 0.0 % | 0.0 % | -15.4 | 10.1 % | 1.9 % | — |
| AUID authID Inc. | 08/13 | -27 % | 73 7/25 | Stage 4 | C 45 | 4 of 9 | 0.0 $ | Software - Infrastructure | – | — | — | Technology | 0.71 $ | +17.8 % | +2.9 % | -80.3 % | −82.3 % | — | 6 | 42 | 6.7 % | 8.5 % | 1.57 | — | 0.0 | 5.9 | — | — | — | -0.5 | — | 100.0 % | 0.0 % | -281.5 % | -139.0 % | — | — | +130.2 % | 5 | 0.0 % | 0.0 % | -109.6 | 13.6 % | 6.2 % | — |
| TIL Instil Bio Inc. | 08/12 | -20 % | 89 8/22 | Stage 4 | D 29 | 4 of 9 | 0.0 $ | Biotechnology | Neutral | — | — | Healthcare | 7.20 $ | -31.3 % | -34.3 % | -67.5 % | −78.0 % | -6.2 % | 6 | 42 | 4.3 % | 2.9 % | 1.91 | — | 0.0 | — | 0.5 | — | — | 0.6 | — | — | 0.0 % | -37.1 % | -12.7 % | 0.77 | — | -100.0 % | 2 | 0.0 % | 0.0 % | -2.7 | 62.2 % | 5.8 % | — |
| AKBA Akebia Therapeutics, Inc. | 08/06 | +3 % | 29 3/22 | Stage 4 | D 32 | 1 of 9 | 0.3 $ | Drug Manufacturers - Specialty & Generic | – | — | — | Healthcare | 1.30 $ | -31.7 % | -34.7 % | -64.8 % | −74.5 % | +223.1 % | 5 | 42 | 7.0 % | 7.4 % | 0.24 | — | 28.7 | 1.5 | 14.0 | 5.7 | — | 66.9 | — | 81.9 % | -8.8 % | -79.0 % | 2.0 % | 0.46 | — | +47.5 % | 5 | 0.0 % | 0.0 % | -10.8 | 42.1 % | 7.2 % | 4.8 (4) |
| HUMA Humacyte Inc | 08/10 | -26 % | 16 2/22 | Stage 4 | D 34 | 2 of 9 | 0.2 $ | Biotechnology | – | — | — | Healthcare | 0.69 $ | -27.1 % | -26.0 % | -69.8 % | −78.2 % | +230.6 % | 5 | 42 | 14.9 % | 12.7 % | 2.52 | — | 35.8 | 89.5 | 18.1 | — | — | 4.3 | — | -4,053.7 % | 0.0 % | -409.5 % | -51.5 % | 5.67 | — | -100.0 % | 2 | 0.0 % | 0.0 % | -21.1 | 22.3 % | 13.7 % | — |
| BYND Beyond Meat Inc | 08/05 | -33 % | 28 2/16 | Stage 4 | D 26 | 4 of 9 | 0.3 $ | Packaged Foods | – | — | — | Consumer Defensive | 0.61 $ | -17.3 % | -28.2 % | -78.7 % | −91.1 % | +2.9 % | 5 | 42 | 6.9 % | 6.9 % | 2.75 | — | 5,000.0 | 1.2 | 52.9 | — | 40.75 | 2.2 | — | 10.8 % | 95.0 % | -1,167.0 % | -17.0 % | -23.58 | — | -15.6 % | 2 | 0.0 % | 0.0 % | -4.6 | 38.1 % | 28.9 % | — |
| RPID Rapid Micro Biosystems Inc | 08/11 | +24 % | 30 3/22 | Stage 4 | D 37 | 2 of 9 | 0.1 $ | Medical Devices | – | — | — | Healthcare | 2.10 $ | -41.7 % | -44.2 % | -36.0 % | −65.6 % | +292.2 % | 5 | 42 | 4.3 % | 6.4 % | 1.47 | — | 0.0 | 3.3 | — | — | — | 0.8 | — | 2.9 % | -145.8 % | -116.7 % | -41.9 % | — | — | +19.7 % | 6 | 0.0 % | 0.0 % | -26.3 | 54.1 % | 2.0 % | — |
| SRFM Surf Air Mobility Inc. | 08/11 | — | 9 2/29 | Stage 4 | D 32 | 4 of 9 | 0.1 $ | Airlines | – | — | — | Industrials | 0.79 $ | -45.9 % | -56.3 % | -80.2 % | −90.8 % | +483.8 % | 5 | 42 | 12.5 % | 9.2 % | 2.76 | — | 0.0 | 0.7 | 2.1 | — | — | -0.6 | — | 4.7 % | -103.4 % | 0.0 % | -39.6 % | -1.60 | — | -10.8 % | 4 | 0.0 % | 0.0 % | -29.5 | 19.1 % | 14.5 % | — |
| CTSO Cytosorbents Crp | 08/06 | -29 % | 98 11/22 | Stage 4 | D 39 | 4 of 9 | 0.0 $ | Medical Devices | – | — | — | Healthcare | 0.37 $ | -32.9 % | -44.6 % | -57.7 % | −64.6 % | +525.0 % | 4 | 42 | 18.1 % | 13.4 % | 1.39 | — | 7.2 | 0.7 | — | — | — | -1.9 | — | 71.0 % | -31.9 % | -141.6 % | -18.3 % | — | — | +4.1 % | 3 | 0.0 % | 0.0 % | -23.5 | 26.4 % | 3.6 % | — |
| SER Serina Therapeutics Inc | 08/10 | -32 % | 30 3/22 | Stage 4 | D 31 | 4 of 9 | 0.0 $ | Biotechnology | – | — | — | Healthcare | 2.10 $ | +0.4 % | -58.3 % | -61.1 % | −77.0 % | +422.0 % | 4 | 16 | 10.6 % | 9.9 % | 0.03 | — | 0.0 | 330.0 | 2.5 | — | — | 37.4 | — | -10,210.0 % | 0.0 % | -221.9 % | -89.8 % | 0.18 | — | +132.1 % | 3 | 0.0 % | 0.0 % | -3.6 | 9.8 % | 3.3 % | — |
| VERI Veritone Inc | 08/06 | -22 % | 20 3/25 | Stage 4 | D 29 | 4 of 9 | 0.1 $ | Software - Infrastructure | – | — | — | Technology | 1.10 $ | -69.5 % | -74.5 % | -48.1 % | −86.4 % | +476.2 % | 4 | 91 | 7.7 % | 7.5 % | 2.29 | — | 666.7 | 1.1 | 2.1 | — | — | 54.0 | — | 68.5 % | -123.8 % | -349.4 % | -27.8 % | 0.93 | — | -0.5 % | 2 | 0.0 % | 0.0 % | -14.4 | 25.7 % | 12.2 % | — |
| XCUR Exicure Inc | 08/14 | -25 % | 71 6/22 | Stage 4 | D 35 | 3 of 9 | 0.0 $ | Biotechnology | – | — | — | Healthcare | 1.60 $ | -49.6 % | -63.3 % | -77.1 % | −73.5 % | -20.6 % | 4 | 42 | 18.0 % | 12.5 % | 3.60 | — | 0.0 | — | — | — | — | 0.0 | — | — | 0.0 % | -145.2 % | -32.5 % | — | — | -100.0 % | 2 | 0.0 % | 0.0 % | -55.1 | 2.7 % | 0.5 % | — |
| VEEA Veea Inc. | 08/18 | — | 97 12/25 | Stage 4 | D 36 | 4 of 9 | 0.0 $ | Information Technology Services | – | — | — | Technology | 0.16 $ | -48.2 % | -60.7 % | -89.2 % | −84.5 % | — | 3 | 42 | 16.5 % | 14.0 % | 0.32 | — | 0.0 | 25.0 | — | — | — | 164.5 | — | 79.3 % | 0.0 % | 0.0 % | -42.4 % | — | — | +56.6 % | 1 | 0.0 % | 0.0 % | -25.4 | 3.2 % | 1.6 % | — |
| MVIS Microvision Inc | 08/06 | -31 % | 47 5/25 | Stage 4 | D 36 | 4 of 9 | 1.4 $ | Scientific & Technical Instruments | – | — | — | Technology | 3.90 $ | -58.5 % | -67.2 % | -76.5 % | −82.1 % | +545.2 % | 2 | 42 | 11.0 % | 10.1 % | 1.23 | — | 0.0 | 924.7 | — | — | — | -13.1 | — | -1,095.0 % | 0.0 % | -197.3 % | -41.9 % | — | — | -74.3 % | 4 | 0.0 % | 0.0 % | -30.1 | 25.9 % | 19.9 % | — |
| DOMO Domo Inc | — | -28 % | 20 3/25 | Stage 4 | C 47 | 4 of 9 | 0.2 $ | Software - Application | – | — | — | Technology | 3.90 $ | -73.4 % | -67.9 % | -75.7 % | −86.8 % | +77.6 % | 2 | 42 | 18.3 % | 12.0 % | 1.80 | — | 0.0 | 0.6 | — | 875.0 | — | -6.3 | — | 74.9 % | -17.4 % | 0.0 % | -10.5 % | — | — | +0.6 % | 3 | 0.0 % | 0.0 % | -33.1 | 65.1 % | 8.5 % | — |
| HRTX Heron Therapeuti | 08/14 | -22 % | 29 3/22 | Stage 4 | D 29 | 3 of 9 | 0.1 $ | Biotechnology | – | — | — | Healthcare | 0.51 $ | -67.8 % | -66.0 % | -69.7 % | −82.2 % | +387.8 % | 2 | 42 | 7.0 % | 8.8 % | 1.65 | — | 46.9 | 0.7 | — | — | — | 35.0 | — | 62.8 % | -20.5 % | -2,408.9 % | -2.7 % | — | — | +7.4 % | 2 | 0.0 % | 0.0 % | -19.6 | 83.3 % | 28.2 % | — |
| CDLX Cardlytics Inc | 08/05 | -32 % | 75 7/24 | Stage 4 | D 38 | 3 of 9 | 0.0 $ | Advertising Agencies | – | — | — | Communication Services | 4.10 $ | -53.6 % | -60.1 % | -78.4 % | −22.3 % | +116.3 % | 2 | 13 | 7.3 % | 9.4 % | 0.62 | — | 36.5 | 0.1 | 1.8 | 3.9 | — | -7.7 | — | 47.5 % | -44.8 % | -356.0 % | -7.7 % | -52.47 | — | -16.2 % | 3 | 0.0 % | 0.0 % | -14.8 | 29.9 % | 13.1 % | — |
| ELTX Elicio Therapeutics Inc. | 08/06 | -20 % | 57 5/22 | Stage 1 | E 22 | 3 of 9 | 0.1 $ | Biotechnology | – | — | — | Healthcare | 2.90 $ | -48.4 % | -51.2 % | -71.3 % | −76.6 % | +433.3 % | 2 | 42 | 34.2 % | 18.0 % | 1.79 | — | 0.0 | — | 102.7 | — | — | -2.6 | — | — | 0.0 % | -1,076.3 % | -92.4 % | -9.98 | — | -100.0 % | 3 | 0.0 % | 0.0 % | -41.0 | 17.0 % | 14.8 % | — |
| PSQH PSQ Holdings Inc. | 08/11 | -33 % | 20 3/25 | Stage 4 | C 45 | 4 of 9 | 0.0 $ | Software - Application | – | — | — | Technology | 4.40 $ | -56.7 % | -64.3 % | -85.1 % | −86.4 % | +1,053.8 % | 2 | 42 | 7.5 % | 8.0 % | 0.44 | — | 0.0 | 0.5 | — | — | — | -3.8 | — | 63.2 % | -165.6 % | -170.8 % | -29.4 % | — | — | -21.6 % | 5 | 0.0 % | 0.0 % | -8.8 | 15.6 % | 0.0 % | — |
| ADCT ADC Therapeutics SA | 08/11 | -15 % | 28 3/22 | Stage 4 | D 41 | 4 of 9 | 0.1 $ | Biotechnology | – | — | — | Healthcare | 1.10 $ | -67.4 % | -70.8 % | -61.0 % | −79.1 % | +380.8 % | 1 | 42 | 8.7 % | 10.5 % | 1.88 | — | 0.0 | 1.8 | 3.6 | — | — | -1.4 | — | -26.3 % | -173.0 % | -705.5 % | -22.7 % | -0.54 | — | +14.9 % | 3 | 0.0 % | 0.0 % | -13.1 | 67.6 % | 5.6 % | — |
| GOSS Gossamer Bio Inc | 08/04 | -29 % | 89 8/22 | Stage 4 | C 48 | 3 of 9 | 0.1 $ | Biotechnology | Uses AI | — | Healthcare | 0.17 $ | -94.5 % | -95.2 % | -91.3 % | −95.7 % | +2,168.2 % | 1 | 42 | 11.9 % | 13.1 % | 2.05 | — | 0.0 | 1.5 | 2.7 | — | — | -0.4 | — | 100.0 % | 0.0 % | -783.4 % | -52.3 % | -1.26 | — | -57.7 % | 2 | 0.0 % | 0.0 % | -40.3 | 75.2 % | 11.7 % | — | |
| MDXH MDxHealth SA ADR | 08/13 | -33 % | 7 1/22 | Stage 4 | C 46 | 4 of 9 | 0.0 $ | Diagnostics & Research | – | — | — | Healthcare | 0.46 $ | -85.6 % | -88.5 % | -81.3 % | −91.5 % | +544.4 % | 1 | 42 | 9.1 % | 10.9 % | -503,341.44 | — | 27.7 | 0.2 | 23.9 | — | — | 17.6 | — | 63.7 % | -29.9 % | -2,440.4 % | -6.4 % | -7.86 | — | +19.8 % | 4 | 0.0 % | 0.0 % | -6.8 | 48.5 % | 0.3 % | — |
Price Chart
Quarterly Figures
No quarterly data available.
Frequently Asked Questions
Altmans Insolvenz-Frühwarnung in Reinform: Z″-Score im jüngsten UND in jedem verfügbaren Quartal in der Distress-Zone (< 1,1), dazu schwache Zinsdeckung (< 3). Anders als der strengere Going-Concern-Scanner (der zusätzlich negativen operativen Cashflow verlangt) zeigt dieser Scanner alle Titel, die dauerhaft in der roten Zone notieren.
All scanners are recalculated daily across the entire stock universe — most recently on 3. August 2026. The data basis is fundamental data and SEC filings (10-K annual reports and 10-Q quarterly reports).
Currently, 92 stocks pass this scanner's criteria (as of 3. August 2026).
Global filters: market cap of $50B or less (mega caps are cut from every scanner); 10- and 30-day ADR must be ≥ 1% (too little movement gets cut); fundamentally healthy names (Piotroski ≥ 5 or Fundamental Rating ≥ 55 out of 100) are excluded.
This scanner deliberately hunts for red flags — a hit is a finding, not a recommendation: like a smoke detector that beeps so you look in time. A hit is also not a bankruptcy verdict; most companies save themselves (say, through a capital raise, which dilutes existing shareholders). Portfolio owners use the list as an early-warning system, bargain hunters as an anti-shopping list, experienced traders as a watch list — it is never a buy or short recommendation.
Related scanners
- Abwärts-Momentum
- Beneish M-Score
- Going Concern (Distress-Proxy)
- Insolvenz-Studie: gestapelte Warnsignale
- Insolvenzgefahr-Radar: Kasse bald leer
- Kathy Donnelly: Liquid Movers Down
- Mike Webster: Überreizt (Webby RSI)
- Nahe 52-Wochen-Tief
- Pradeep Bonde: $ Breakout Bearish
- Pradeep Bonde: 4% Breakout Bearish
- Qullamaggie: Parabolic (Short-Watch)
- RS-Schwäche (≤10)
- Schwäche-Cluster
- Stage 4 (Abwärtstrend)
- Stan Weinstein: Stage 4
- Stan Weinstein: Stage 4B-
- Thomas Inso Kandidat
- Unter 50- & 200-SMA
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.